ArticleBrain communications2026
Sex differences in dengue-related neurological complications: insights from the 2023 Taiwan outbreak.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a prevalent vector-borne disease that threatens nearly half of the world's population. Although not traditionally classified as neurotropic, dengue can lead to a wide range of neurological manifestations beyond the conventional spectrum of disease severity. This study investigated neurological manifestations during the 2023 dengue outbreak in Tainan, Taiwan, with a focus on the observed male predominance in symptomatic and severe cases. In 2023, the national infectious disease reporting system recorded 21 513 dengue cases in Tainan, of whom 53% were male. Among these, 768 patients (56.4% male; 10.2% paediatric) required hospitalization in tertiary medical centres. Neurological manifestations were observed in 12.0% of hospitalized patients, corresponding to 0.43% of all reported dengue cases in the Tainan area. Among hospitalized patients, neurological manifestations included encephalitis (0.4%), myelitis (0.1%), myositis (7.8%), encephalopathy (2.0%), intracranial haemorrhage (1.0%), ischaemic stroke (0.9%), myasthenia gravis (0.4%), seizures (1.0%), Guillain-Barré syndrome (0.8%), and opsoclonus-myoclonus syndrome (0.1%). Myositis was the most common neurological manifestation, occurring in 26.9% of paediatric and 5.7% of adult patients. Risk factors for neurological complications included male sex, coexisting chronic kidney disease, and neurodegenerative disorders. Male patients showed a higher likelihood of symptomatic dengue infection in the overall population (odds ratio 1.15, 95% confidence interval 1.12-1.18), as well as increased risks of severe disease, hospitalization in tertiary medical centres (crude odds ratio 1.25, 95% confidence interval 1.06-1.46), and neurological complications (adjusted odds ratio 2.37, 95% confidence interval 1.32-4.26) among those older than 40 years. Although the overall case fatality rate in 2023 was 0.9 per 1000 cases, neurological complications were relatively frequent among hospitalized patients. These findings highlight the need for heightened clinical awareness of dengue-associated neurological complications, particularly among neurologists. The consistent male predominance across symptomatic infection, hospitalization, and neurological involvement suggests that sex may be an independent determinant of dengue severity and neurological risk, especially in older adults. Incorporating sex-specific risk stratification and comprehensive neurological assessment into dengue care may improve early detection and clinical management during future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.